FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204227602> ?p ?o ?g. }

• W3204227602 endingPage "100391" @default.
• W3204227602 startingPage "100391" @default.
• W3204227602 abstract "Drug resistance and the lack of molecular therapeutic target are the main challenges in the management of osteosarcomas (OSs). Identification of novel genetic alteration(s) related with OS recurrence and chemotherapeutic resistance would be of scientific and clinical significance.To identify potential genetic alterations related with OS recurrence and chemotherapeutic resistance, the biopsies of a 20-year-old male osteosarcoma patient were collected at primary site (p-OS) and from its metastatic tumor (m-OS) formed after 5 months of adjuvant chemotherapy. Both OS specimens were subjected to cancer-targeted next generation sequencing (NGS) and their cell suspensions were cultured under three-dimensional condition to establish spheroid therapeutic model. Transcript-oriented Sanger sequencing for GPC3, the detected mutated gene, was performed on RNA samples of p-OS and m-OS tissues and spheroids. The effects of anti-GPC3 antibody and its combination with cisplatin on m-OS spheroids were elucidated.NGS revealed 4 mutations (GPC3, SOX10, MDM4 and MAPK8) and 6 amplifications (MDM2, CDK4, CCND3, RUNX2, GLI1 and FRS2) in p-OS, and 3 mutations (GPC3, SOX10 and EGF) and 10 amplifications (CDK4, CCND3, MDM2, RUNX2, GLI1, FRS2, CARD11, RAC1, SLC16A7 and PMS2) in m-OS. Among those alterations, the mutation abundance of GPC3 was the highest (56.49%) in p-OS and showed 1.54 times increase in m-OS. GPC3 transcript-oriented Sanger sequencing confirmed the mutation at 1046 in Exon 4, and immunohistochemical staining showed increased GPC3 production in m-OS tissues and its spheroids. EdU cell proliferation and Calcein/PI cell viability assays revealed that of the anti-OS first line drugs (doxorubicin, cisplatin, methotrexate, ifosfamide and carboplatin), 10 μM carboplatin exerted the best inhibitory effects on the p-OS but not the m-OS spheroids. 2 μg/mL anti-GPC3 antibody effectively committed m-OS spheroids to death by itself (76.43%) or in combination with cisplatin (92.93%).This study demonstrates increased abundance and up-regulated expression of mutant GPC3 in metastatic osteosarcoma and its spheroids with multidrug resistance. As GPC3-targeting therapy has been used to treat hepatocellular carcinomas and it is also effective to OS PDSs, GPC3 would be a novel prognostic parameter and therapeutic target of osteosarcomas." @default.
• W3204227602 created "2021-10-11" @default.
• W3204227602 creator A5003297103 @default.
• W3204227602 creator A5013544394 @default.
• W3204227602 creator A5014068004 @default.
• W3204227602 creator A5014546886 @default.
• W3204227602 creator A5017417518 @default.
• W3204227602 creator A5022690217 @default.
• W3204227602 creator A5044235001 @default.
• W3204227602 creator A5053738554 @default.
• W3204227602 creator A5057043017 @default.
• W3204227602 creator A5057117256 @default.
• W3204227602 creator A5061396145 @default.
• W3204227602 creator A5071773009 @default.
• W3204227602 creator A5078934307 @default.
• W3204227602 creator A5088141052 @default.
• W3204227602 date "2021-10-01" @default.
• W3204227602 modified "2023-10-12" @default.
• W3204227602 title "Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target" @default.
• W3204227602 cites W1914351667 @default.
• W3204227602 cites W1980088710 @default.
• W3204227602 cites W1984068087 @default.
• W3204227602 cites W1986871224 @default.
• W3204227602 cites W1988325237 @default.
• W3204227602 cites W1999914295 @default.
• W3204227602 cites W2011777894 @default.
• W3204227602 cites W2013881151 @default.
• W3204227602 cites W2014797043 @default.
• W3204227602 cites W2023150137 @default.
• W3204227602 cites W2044702943 @default.
• W3204227602 cites W2083463213 @default.
• W3204227602 cites W2096283457 @default.
• W3204227602 cites W2103441770 @default.
• W3204227602 cites W2106285087 @default.
• W3204227602 cites W2113221009 @default.
• W3204227602 cites W2119180969 @default.
• W3204227602 cites W2122395637 @default.
• W3204227602 cites W2127748864 @default.
• W3204227602 cites W2138601221 @default.
• W3204227602 cites W2139619092 @default.
• W3204227602 cites W2146684965 @default.
• W3204227602 cites W2189936813 @default.
• W3204227602 cites W2255555283 @default.
• W3204227602 cites W2329218644 @default.
• W3204227602 cites W2337209831 @default.
• W3204227602 cites W2341498785 @default.
• W3204227602 cites W2345967497 @default.
• W3204227602 cites W2510482925 @default.
• W3204227602 cites W2519953954 @default.
• W3204227602 cites W2527539743 @default.
• W3204227602 cites W2560367415 @default.
• W3204227602 cites W2611387862 @default.
• W3204227602 cites W2616354594 @default.
• W3204227602 cites W2624710378 @default.
• W3204227602 cites W2725107014 @default.
• W3204227602 cites W2757164733 @default.
• W3204227602 cites W2765565477 @default.
• W3204227602 cites W2769376743 @default.
• W3204227602 cites W2773653224 @default.
• W3204227602 cites W2773981699 @default.
• W3204227602 cites W2784530807 @default.
• W3204227602 cites W2790157952 @default.
• W3204227602 cites W2794820058 @default.
• W3204227602 cites W2799414294 @default.
• W3204227602 cites W2803314509 @default.
• W3204227602 cites W2807088563 @default.
• W3204227602 cites W2883606492 @default.
• W3204227602 cites W2889331509 @default.
• W3204227602 cites W2892617983 @default.
• W3204227602 cites W2892650455 @default.
• W3204227602 cites W2899285497 @default.
• W3204227602 cites W2915238057 @default.
• W3204227602 cites W2916357429 @default.
• W3204227602 cites W2936042979 @default.
• W3204227602 cites W2939543377 @default.
• W3204227602 cites W2945616121 @default.
• W3204227602 cites W2948356525 @default.
• W3204227602 cites W2951912016 @default.
• W3204227602 cites W2978373708 @default.
• W3204227602 cites W2981655388 @default.
• W3204227602 cites W2999417355 @default.
• W3204227602 cites W3011748021 @default.
• W3204227602 cites W3014449779 @default.
• W3204227602 cites W3031366616 @default.
• W3204227602 cites W3092841245 @default.
• W3204227602 cites W3142489198 @default.
• W3204227602 cites W3178804738 @default.
• W3204227602 cites W4235857807 @default.
• W3204227602 cites W4241813594 @default.
• W3204227602 doi "https://doi.org/10.1016/j.jbo.2021.100391" @default.
• W3204227602 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8476350" @default.
• W3204227602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34611509" @default.
• W3204227602 hasPublicationYear "2021" @default.
• W3204227602 type Work @default.
• W3204227602 sameAs 3204227602 @default.
• W3204227602 citedByCount "6" @default.
• W3204227602 countsByYear W32042276022022 @default.
• W3204227602 countsByYear W32042276022023 @default.

• next